- Home
- FEBO vs CLDI Comparison
FEBO vs CLDI Comparison
Compare FEBO & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- CLDI
- Stock Information
- Founded
- FEBO 1993
- CLDI 2014
- Country
- FEBO Hong Kong
- CLDI United States
- Employees
- FEBO N/A
- CLDI N/A
- Industry
- FEBO
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FEBO
- CLDI Health Care
- Exchange
- FEBO Nasdaq
- CLDI Nasdaq
- Market Cap
- FEBO 13.5M
- CLDI 15.7M
- IPO Year
- FEBO 2023
- CLDI N/A
- Fundamental
- Price
- FEBO $1.40
- CLDI $0.42
- Analyst Decision
- FEBO
- CLDI Strong Buy
- Analyst Count
- FEBO 0
- CLDI 2
- Target Price
- FEBO N/A
- CLDI $15.00
- AVG Volume (30 Days)
- FEBO 5.9K
- CLDI 210.4K
- Earning Date
- FEBO 05-27-2025
- CLDI 05-14-2025
- Dividend Yield
- FEBO N/A
- CLDI N/A
- EPS Growth
- FEBO N/A
- CLDI N/A
- EPS
- FEBO N/A
- CLDI N/A
- Revenue
- FEBO $17,110,653.00
- CLDI N/A
- Revenue This Year
- FEBO N/A
- CLDI N/A
- Revenue Next Year
- FEBO N/A
- CLDI N/A
- P/E Ratio
- FEBO N/A
- CLDI N/A
- Revenue Growth
- FEBO 9.01
- CLDI N/A
- 52 Week Low
- FEBO $0.93
- CLDI $0.35
- 52 Week High
- FEBO $17.68
- CLDI $4.90
- Technical
- Relative Strength Index (RSI)
- FEBO 62.78
- CLDI 37.49
- Support Level
- FEBO $1.30
- CLDI $0.41
- Resistance Level
- FEBO $1.49
- CLDI $0.46
- Average True Range (ATR)
- FEBO 0.11
- CLDI 0.04
- MACD
- FEBO 0.01
- CLDI 0.00
- Stochastic Oscillator
- FEBO 76.92
- CLDI 19.97
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.